Objective: Intraurethral alprostadil and oral sildenafil are useful in selected patients. However, there continues to be a significant treatment failure rate. Since their mechanisms of action are different, we wanted to evaluate the effectiveness of combination therapy.Materials and Methods: Of 214 patients treated for erectile dysfunction (ED), 65 were not fully satisfied with the firmness of their erections via monotherapy. Responses were evaluated using the International Index for Erectile Function (IIEF) questionnaire before and after treatment. Group I consisted of 33 patients who tried maximal dose intraurethral alprostadil monotherapy initially, followed by the maximal dose of sildenafil monotherapy, and were still unsatisfied. Group II consisted of 32 patients who tried the maximal dose sildenafil monotherapy initially, followed by the maximal dose of alprostadil monotherapy, and were also unsatisfied. There 65 patients then underwent combination therapy.Results: 60 out of the 65 patients stated they were satisfied with combination therapy. Questionnaire scores for erectile function were 23.1±2.0 (114%) for combination therapy vs. 19.2±1.8 (77%) and 15.2±1.6 (41%) for sildenafil and alprostadil monotherapies (p<0.05). There were no significant differences in responses between the two groups. The men also reported improvement in intercourse and overall satisfaction.Conclusions: Combination therapy may be an option for motivated patients who have a suboptimal response from monotherapy.

Keywords:
Erectile dysfunction, Alprostadil, Sildenafil, Questionnaire
1.
NIH Consensus Development Panel on Impotence. JAMA 1993;269:83–90.
2.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mc–Kinlay JB: Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54–59.
3.
O’Leary MP, Fowler FJ, Lenderking WR, Sagnier P, Guess HA, Barry MJ: A brief male sexual function inventory for urology. Urology 1993;46:697–701.
4.
Montague DK, Barada JH, Belker AM, Levine LA, Nadig PW, Roehrborn CG, Sharlip ID, Bennett AH: Clinical guidelines panel on erectile dysfunction: Summary report on the treattreatment of organic erectile dysfunction. J Urol 1996;156:2007–2010.
5.
Guiliano F, Blanchet P, Banzet O, Lancrenon S, Benoit G, Jardin A: Erection disorders: Efficacy and tolerability after 6 months of intracavernous self–injections of alprostadil. Groupe Français d’étude de l’alprostadil. Press Méd 1994;23:1516–1519.
6.
Linet OI, Ogrinc FG: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996;224:873–878.
7.
Lakin MM, Montague DK, Vanderbug–Medendorp S, Tesar L, Schover LR: Intracavernous injection therapy: Analysis of results and complications. J Urol 1990;143:1138– 1142.
8.
Shenfeld O, Hanani J, Shalhave A et al: Papaverine–phentolamine and prostaglandin E1 vs. papaverine–phentolamine alone for intracorporeal injection therapy: A clinical double–blind study. J Urol 1995;154:1017–1021.
9.
Padma–Nathan H, Hellstrom WJG, Kaiser FE, Labasky RF, Lue TF, Nolten WE, Norwood PC, Peterson CA, Shabsigh R, Tam PY, Place VA, Gesundheit N: Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997;336:1–7.
10.
Fulgham PF, Cochran JS, Denman JL, Feagins BA, Gross MB, Kadesky KT, Kadesky MC, Clark AR, Roehrborn CG: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. J Urol 1998;160:2041–2046.
11.
Goldstein I, Lue TF, Padma–Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397–1403.
12.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The Internationa Index of Erectile Function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–830.
13.
Lue TF: Physiology of penile erection and pathophysiology of erectile dysfunction and priapism; in Walsh PC, Retik AB, Stamey TA, Vaughan ED Jr (eds): Campbell’s Urology, ed 7. Philadelphia, Saunders, 1997, pp 1–1157.
14.
Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90–96.
15.
Moreland RB, Goldstein I, Traish A: Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells. Life Sci 1998;62:309–318.
16.
Wilke RJ, Glick HA, McCarron TJ, Erder MH, Althof SE, Linet OL: Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997;157:2124–2129.
17.
Condra M, Morales A, Surridge DH, Owen JA, Marshall P, Fenemore J: The unreliability of nocturnal penile tumescence recording as an outcome in the treatment of organic impotence J Urol 1986;135:280–284.
18.
Helgason AR, Arver S, Adolfsson J, Dickman P, Granath F, Steineck G: ‘Potency’: the validation of information from a self–administered questionnaire using objective measurements of night–time erections and test–retest reliability. Br J Urol 1998;81:135–141.
19.
Riley AJ, Athanasiadis L: Impotence and its non–surgical management. Br J Clin Pract 1997;51:99–103.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.